: Noted for its inhaled therapy for pulmonary arterial hypertension and its recent pursuit of FDA pediatric approval.
The primary catalyst is upcoming clinical data for ulcerative colitis, expected in the second half of 2027. best biotech stocks to buy under $10
The company recently expanded its pipeline by acquiring DMX-200 for kidney disease. : Noted for its inhaled therapy for pulmonary
: Highlighted for strengthening its global reach through strategic deals, such as the one with Kyowa Kirin. best biotech stocks to buy under $10
It maintains significant institutional interest, with roughly 31 hedge fund holders reported. :
Currently receiving an from analysts at Wolfe Research , with a price target of $7.
Identified as a top pick for its focus on like Fabry and Pompe disease.
